Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N15/86—Viral vectors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
  • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
  • C07K14/4702—Regulators; Modulating activity
  • C07K14/4703—Inhibitors; Suppressors
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/82—Translation products from oncogenes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
  • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
  • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
  • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
  • C12N2750/00011—Details
  • C12N2750/14011—Parvoviridae
  • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
  • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
  • C12N2750/00011—Details
  • C12N2750/14011—Parvoviridae
  • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
  • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
  • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
  • C12N2750/00011—Details
  • C12N2750/14011—Parvoviridae
  • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
  • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
  • C12N2750/14145—Special targeting system for viral vectors
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2800/00—Nucleic acids vectors
  • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2830/00—Vector systems having a special element relevant for transcription
  • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2830/00—Vector systems having a special element relevant for transcription
  • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2830/00—Vector systems having a special element relevant for transcription
  • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Definitions

• NF2 Neurofibromatosis 2
• NF2 is a rare genetic disorder caused by germline mutations in the NF2 gene encoding Merlin, a tumor suppressor protein. These mutations lead to deficiency in Merlin protein which regulates cellular processes including contact inhibition, proliferation, and apoptosis.
• NF2 is characterized by slow-growing tumors, such as: schwannomas (which arise from Schwann cells), meningiomas (which arise from arachnoid cells), ependymomas (which arise from ependymal cells), as well as juvenile cataracts, and retinal hamartomas.
• Typical presentation of NF2 includes bilateral vestibular schwannoma which are multilobular masses occurring on the eighth cranial nerve.
• Vestibular schwannomas cause hearing loss, ringing in the ears, deafness, dizziness, and loss of balance.
• Patients typically become deafened either because of the effects of tumor growth (including ototoxic effects on the ear leading to death of the cells in the inner ear involved in sensation of sound) or interventions to manage the tumors (including partial or complete removal of the auditory nerve). Left unmanaged, these tumors can eventually compress the brain stem and cause death. Additional symptoms may include disfigurement, facial weakness, headache, and vision loss.
• Meningiomas occur in the meninges, the lining of the brain or spinal cord, and originate in arachnoid cells. The median number of meningiomas these patients develop is three. Over 33% of the tumors are characterized as growing significantly (> 1 mm/year). Additionally, meningiomas can also occur in sporadic (non-NF2) patients due to somatic mutations in the NF2 gene. Sporadic meningiomas are the most common brain tumor ( ⁇ 35% of all brain tumors) and can cause neurological deficits due to compression of brain or spine. Occurrence of meningiomas is the greatest driver of permanent morbidity and mortality in NF2 patients.
• NF2 patients are at increased risk for developing spinal ependymomas. These tumors arise from ependymal cells and typically occur within brainstem or spine. Ependymomas often occur in a “string of pearls” pattern with multiple lesions in the cervical spine. Only a subset of ependymomas will require treatment.
• the standard approach is surgical resection with radiation reserved for lesions that recur after surgical resection.
• cranial nerve or vestibulocochlear nerve
• patients with NF2 commonly develop schwannomas on other cranial nerves including: CN3: oculomotor, CN4: trochlear, CN5: trigeminal, CN6: abducens, CN7: facial, CN9: glossopharyngeal, CN10: vagal, CN11: spinal accessory, CN12: hypoglossal. Damage or loss of function in any of those nerves can cause a wide variety of conditions in the head and neck.
• NF2 patients may also develop a number of conditions of the eye including: cataracts, retinal detachment, damage to the nerves of the eye, papilledema (optic disc edema), ocular migraine (retinal migraine), retinitis pigmentosa (RP) (retinal degeneration), combined hamartoma of the retina and RPE, retinal microaneurysms, epiretinal membrane conjunctivitis, physiopedia (severe dry eyes), nystagmus-oscillopsia (ocular flutter/cross), diplopia (double vision), and gaze-evoked tinnitus (GET).
• cataracts cataracts, retinal detachment, damage to the nerves of the eye
• papilledema optical disc edema
• ocular migraine retinal migraine
• RP retinitis pigmentosa
• GET gaze-evoked tinnitus
• compositions and methods for treating NF2 patients fulfills these needs as well as others.
• an adeno-associated virus comprising an adeno associated virus capsid protein and a transgene encoding a full-length Merlin protein or one or more active fragments thereof, such as, but not limited to residues 1-359 of Isoform 1 of Merlin, residues 1- Merlin, residues 312-595 of Isoform 1 of Merlin, residues, 479-595 of Isoform 1, residues 503- 595 of Isoform 1 of Merlin, or any combination thereof are provided.
• AAV adeno-associated virus
• compositions comprising an AAV as provided for herein are provided.
• compositions comprising an AAV as provided for herein and a pharmaceutically acceptable carrier are provided.
• methods of delivering a Merlin protein to a cell comprising the step of contacting the cell with an AAV as provided for herein.
• methods of treating a subject with NF2 comprising administering to the subject with NF2 an AAV as provided for herein.
• methods of inhibiting the growth of a schwannoma, a meningioma, or an ependymoma in a subject comprising administering to an AAV as provided for herein.
• methods of preventing the growth or formation of a schwannoma, ependymoma or a meningioma in a subject comprising administering to the subject an AAV as provided for herein.
• methods of treating a subject with a disorder, or at risk of a disorder, associated with merlin deficiency comprising administering to the subject an AAV as provided for herein.
• nucleic acid molecule comprising a sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical of SEQ ID NO: 2 is provided herein, or a nucleic acid sequence that encodes the Merlin protein or an active fragment thereof.
• compositions comprising a nucleic acid molecule provided for herein and a carrier are provided.
• methods of producing an AAV as provided herein comprising contacting a cell with a nucleic acid molecule as provided herein to produce the AAV are provided.
• FIG. 1 illustrates a non-limiting vector (plasmid) map of a recombinant DNA plasmid that can be used to generate AAV particles that comprises a nucleic acid molecule encoding for Merlin protein under a CAG promoter to express MERLIN protein.
• plasmid non-limiting vector
• FIG. 2 illustrates a non-limiting vector (plasmid) map of a recombinant DNA plasmid that can be used to generate AAV particles that comprises a nucleic acid molecule encoding for Merlin protein under a CAG promoter to express MERLIN protein, this example includes HPRT stuffer sequence, the posttranscriptional regulatory element of HBV as a well as a modified left AAV2 ITR as compared to the plasmid illustrated in FIG 4.
• the bacterial backbone has been modified using kanamycin selection gene to facilitate testing in human clinical studies.
• FIG. 3 shows an exemplary Western blot that demonstrates that HEK 293T cells transduced with AAV9-CAG-Merlin-v2 can overexpress Merlin (NF2).
• FIG. 4 illustrates exemplary cerebellum tissue sections, which were obtained from cynomolgus macaques at 28 days from administration of AAV9-CAG-Merlin-v2 (2TX-G38) or AAV9-CAG-eGFP (2TX-C10) by intracistemal magna (ICM) injection and are stained against eGFP by immunohistochemistry and demonstrate the cerebellum biodistribution of AAV9-CAG- eGFP.
• ICM intracistemal magna
• FIG. 5 shows example enhanced immunofluorescent micrographs of cervical DRG tissue sections stained for the presence of eGFP, obtained from 2 month old Postn-Cre;Nf2 fl0x/fl0x mice 1 month post administration with AAV9-CAG-GFP by ICM injection, which demonstrate significant biodistribution of eGFP in the DRG of Postn-Cre;Nf2 flox/flox mice injected with AAV9- CAG-GFP into the Ci sterna Magna.
• FIG. 6 shows example enhanced immunofluorescent micrographs of cervical DRG tissue sections stained for the presence of eGFP, obtained from 2 month old Postn-Cre;Nf2 fl0x/fl0x mice 4 weeks post administration with a low dose of (group 3; 5.6 E12 vg/kg) AAV9-CAG-GFP by ICM injection, and demonstrates GFP expression in the SC surrounding the axonal cells in the DRG of said mice.
• FIG. 7 shows example enhanced immunofluorescent micrographs, stained for the presence of eGFP, of tissue sections with nerves distal of the DRG, which were obtained from 2 month old Postn-Cre;Nf2 flox/flox mice 4 weeks post administration with low dose (group 3; 5.6 E12 vg/kg) AAV9-CAG-GFP by ICM injection, and demonstrate that eGFP is also observed in the nerves distal of the DRG of NF2 knockout mice dosed by ICM.
• FIG. 8 is a graph showing the density of Schwann cell (SC) nuclei (nuclei/pm 2 ) in cross- sections of dorsal root ganglia (DRG) from 6 month old Postn-Cre;Nf2 flox/flox mice 5 months from AAV9-CAG-Merlin or AAV9-CAG-GFP administration by ICM injection, which demonstrate that there can be a significant reduction in SC proliferation in NF2 knockout mice administered with AAV9-CAG-Merlin compared to mice injected with the AAV9-CAG-GFP control vector.
• SC Schwann cell
• FIG. 9 is a non-limiting embodiment of a vector map for pAAV CAG Merlin Kan (SEQ ID NO: 7), which can be used to produce AAV particles comprising a nucleic acid molecule encoding for Merlin under control of a CAG promoter.
• This vector map which is similar to FIG. 2, is illustrated with a kanamycin resistant gene to help selection, although other selection genes can be used.
• AAV adeno-associated virus
• AAV adeno-associated virus
• a transgene encoding a full-length Merlin protein (e.g. Isoform 1 of Merlin or Isoform 2 of Merlin) or one, or more, active fragments thereof, such as, but not limited to, residues 1-359 of Isoform 1 of Merlin, residues 1-313 of Isoform 1 of Merlin, residues 1-219 of Isoform 1 of Merlin, residues 1-73 of Isoform 1 of Merlin, residues 312-595 of Isoform 1 of Merlin, residues 479-595 of Isoform 1, residues 503-595 of Isoform 1 of Merlin, or combination thereof.
• AAV adeno-associated virus
• the AAV of embodiment 4, wherein the promoter is a constitutive or tissue specific promoter, such as, but not limited to, a neuron or neuronal tissue specific promoter, including, but not limited to, those provided for herein.
• the AAV of embodiment 5, wherein the promoter is a CAG promoter, a CMV promoter, CB A promoter, or an SV40 promoter.
• the capsid protein is an AAV9 capsid protein.
• AAV9 capsid protein comprises a protein having the amino acid sequence of: amino acid residues 1 to 736 of SEQ ID NO: 3; amino acid residues 138 to 736 of SEQ ID NO: 3; or amino acid residues 203 to 736 of SEQ ID NO: 3.
• AAV9 capsid comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to amino acid residues 203 to 736 of SEQ ID NO: 3.
• transgene comprises a nucleic acid molecule encoding a protein comprising the sequence of SEQ ID NO: 1 of SEQ ID NO: 8, or an active fragment thereof.
• the AAV of embodiment 12, wherein the nucleic acid molecule encoding the Merlin protein comprises a nucleic acid sequence of SEQ ID NO: 2, SEQ ID NO: 9, or a codon optimized version of each of the foregoing.
• AAV of embodiment 14, wherein an AAV2 inverted terminal repeat comprises a sequence of SEQ ID NO: 4.
• AAV AAV of any of the preceding embodiments, wherein the AAV comprises a nucleic acid molecule stuff er sequence upstream of the transgene and downstream of the 5’ (left) AAV ITR.
• AAV of embodiment 16 wherein the stuffer sequence comprises a sequence of SEQ ID NO: 6.
• the AAV comprises a nucleotide intron sequence that is downstream of the transgene and upstream of the right (3’) AAV (e g., AAV2) ITR.
• a composition comprising the AAV of any one of embodiments 1-20 and a physiologically compatible carrier.
• a pharmaceutical composition comprising the AAV of any one of embodiments 1-20 and a pharmaceutically acceptable carrier.
• a method of delivering a Merlin protein to a cell comprising the step of contacting the cell with the AAV of any one of embodiments 1-20 or the composition of embodiments 21 or 22.
• a method of treating a subject with NF2 comprising administering to the subj ect with NF2 the AAV of any one of embodiments 1 -20 or the composition of embodiments 21 or 22.
• [0056] 25 The method of embodiment 24, wherein the administration is intraventricular, intracisternal, intrathecal, intrastriatal, intrapleural, intramuscular, intravitreal, intravenous, or intratumoral.
• a method of inhibiting the growth of a schwannoma, a meningioma, or an ependymoma in a subject comprising administering to the subject the AAV of any one of embodiments 1-20 or the composition of embodiments 21 or 22.
• [0060] 29 A method of preventing the growth or formation of a schwannoma, ependymoma or a meningioma in a subject, the method comprising administering to the subject the AAV of any one of embodiments 1-20 or the composition of embodiments 21 or 22.
• 30 The method of embodiment 29, wherein the subject is a subject with NF2 or NF2 deficiency disorder, such as schwannomatosis.
• a method of treating a subject with a disorder, or at risk of a disorder, associated with merlin deficiency comprising administering to the subject the AAV of any one of embodiments 1-20 or the composition of embodiments 21 or 22.
• schwannomatosis e.g., vestibular schwannomas
• a cancer e.g., a hematological cancer (e.g., juvenile myelomonocytic leukemia), a leukemia (e.g., adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia, adult acute myeloid leukemia, childhood acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, or hairy cell leukemia); a lymphoma (e.g., AIDS-related lymphoma, cutaneous T-cell lymphoma, adult hodgkin lymphoma, childhood hodgkin lymphoma, adult non-hodgkin lymphoma, childhood non- hodgkin lymphoma, primary central nervous system lymphom, sezary syndrome,
• a lymphoma e.g., AIDS-related lymphoma, cutaneous T-cell lymph
• [0065] 34 The method of any of embodiments 23-33, wherein the AAV is administered at least every 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 2 years, three years, four years, five years, six years, or more.
• a nucleic acid molecule comprising a sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical, or is identical, to SEQ ID NO: 2.
• nucleic acid molecule of embodiment 30, wherein the nucleic acid molecule is an isolated nucleic acid molecule.
• nucleic acid molecule of embodiments 36 or 37, wherein the nucleic acid molecule comprises a sequence of SEQ ID NO: 2.
• nucleic acid molecule of embodiment 41, wherein one of the AAV2 inverted terminal repeat comprises a sequence of SEQ ID NO: 4.
• nucleic acid molecule of embodiment 44 wherein the regulatory sequences comprises a promoter.
• nucleic acid molecule of embodiment 44 wherein the promoter is a constitutive promoter or a tissue specific promoter.
• the promoter is a CAG promoter, a CMV promoter, or an SV40 promoter.
• AAV e.g. AAV2
• nucleic acid molecule of embodiment 50, wherein the HPRE intron sequence comprises a sequence of SEQ ID NO: 5.
• composition comprising the nucleic acid molecule of any one of embodiments 36-52 and a carrier.
• composition of embodiment 53, wherein the carrier is a transfection reagent [0085] 54.
• a method of producing an AAV particle of any one of embodiments 1-20 the method comprising contacting (e.g. transfecting or electroporating) a cell with a nucleic acid molecule of any one of embodiments 36-52 or the composition of embodiments 53 or 54 to produce the AAV.
• a cultured host cell comprising a recombinant nucleic acid molecule encoding an AAV capsid protein and a recombinant nucleic acid molecule encoding Merlin protein.
• nucleic acid molecule encoding the capsid protein encoding a protein that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical, or is identical, to a protein having the amino acid sequence of: amino acid residues 1 to 736 of SEQ ID NO: 3; amino acid residues 138 to 736 of SEQ ID NO: 3; or amino acid residues 203 to 736 of SEQ ID NO: 3.
• Embodiments provided for herein are directed to, in part, compositions, methods and other embodiments for treating NF2 disease or conditions, tumors, or disorders related to Merlin protein deficiency.
• a recombinant virus that comprises a transgene that encodes for the Merlin protein.
• the type of virus used can be any virus that when used to infect a cell or a subject will lead to the expression of the transgene and the Merlin protein, or any portion thereof, in the cell or in the subject.
• the portion is an N- terminal fragment of the Merlin protein (Tikoo et. al., An Anti-Ras Function of Neurofibromatosis Type 2 Gene Product (NF2/Merlin), The Journal of Biological Chemistry, Vol. 269, No 38, Issue of September 23, 1994 pp. 23387-23390; Cui et.
• the N-terminal fragment of Merlin encoded comprises or consists of amino acid residues 1-359 of Isoform 1 of Merlin. In some embodiments, the N-terminal fragment of Merlin encoded comprises or consists of amino acid residues 1-313 of Isoform 1 of Merlin. In some embodiments, the N-terminal fragment of Merlin encoded comprises or consists of amino acid residues 1-219 of Isoform 1 of Merlin. In some embodiments, the N-terminal fragment of Merlin encoded comprises or consists of amino acid residues 1-73 of Isoform 1 of Merlin.
• the portion is a C-terminal fragment of the Merlin protein (Cui et. al., The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling, Oncogene, Vol. 38, 2019, pp. 6370-6381).
• the C-terminal fragment of Merlin encoded comprises or consists of amino acid residues 312-595 of Isoform 1 of Merlin.
• the C-terminal fragment of Merlin encoded comprises or consists of amino acid residues 479-595 of Isoform 1 of Merlin.
• the C-terminal fragment of Merlin encoded comprises or consists of amino acid residues 503-595 of Isoform 1 of Merlin.
• the “Active Fragment”, as used herein, is a fragment of wild type Merlin that has biological activity.
• the “Isoform”, as used herein, is an alternative splicing variant of wild type Merlin.
• the virus is an adeno-associated virus (AAV).
• AAV has many naturally occurring serotypes that can be used.
• the AAV serotype is AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV-DJ.
• the serotype refers to the capsid protein that is encoded by the particular strain of the AAV.
• the proteins which comprise that capsid proteins of different AAV serotypes can be engineered, or modified from the naturally occurring serotypes, to have enhanced properties.
• an AAV that comprises an AAV capsid protein and a transgene encoding a Merlin protein.
• Methods of making AAV are known in the art and can be found in, for example, U.S. Patent No. 7,906,111, which is hereby incorporated by reference in its entirety.
• the transgene can be incorporated in what can be referred to as a minigene that comprises AAV inverted terminal repeats as well as sequences that encode for the Merlin protein.
• the sequences of the transgene can also be operably linked to regulatory elements or sequences that direct the expression of the Merlin protein in a host cell.
• the regulatory elements can include conventional control elements which are operably linked to the transgene in a manner which permits its transcription, translation and/or expression in a cell transfected with the plasmid vector or infected with the virus.
• operably linked sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest.
• Expression control sequences can include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation (poly A) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product.
• efficient RNA processing signals such as splicing and polyadenylation (poly A) signals
• sequences that stabilize cytoplasmic mRNA sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product.
• a great number of expression control sequences including promoters which are native, constitutive, inducible and/or tissue-specific, are known in the art and may be utilized.
• constitutive promoters include, without limitation, CAG promoter (Miyazaki et al, Gene. 79 (2): 269-77; Niwa et ah, Gene. 108 (2): 193-9), the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) (see, e.g., Boshart et al, Cell, 41:521-530 (1985), the simian virus 40 (SV40) promoter, the dihydrofolate reductase promoter, the beta-actin promoter, the phosphoglycerol kinase (PGK) promoter, the human elongation factor 1 alpha (EF1) promoter (Qin, J.
• CAG promoter Mayazaki et al, Gene. 79 (2): 269-77; Niwa et ah, Gene. 108 (2)
• Inducible promoters allow regulation of gene expression and can be regulated by exogenously supplied compounds, environmental factors such as temperature, or the presence of a specific physiological state, e.g., acute phase, a particular differentiation state of the cell, or in replicating cells only. Inducible promoters and inducible systems are available from a variety of commercial sources. Many other systems have been described and can be readily selected by one of skill in the art.
• inducible promoters regulated by exogenously supplied compounds include, the zinc-inducible sheep metallothionein (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (International Patent Publication No. WO 98/10088); the ecdysone insect promoter (No et al, Proc. Natl. Acad. Sci. USA, 93:3346-3351 (1996)), the tetracycline-repressible system (Gossen et al, Proc. Natl. Acad Sci.
• MT zinc-inducible sheep metallothionein
• Dex dexamethasone
• MMTV mouse mammary tumor virus
• T7 polymerase promoter system International Patent Publication No. WO 98/10088
• ecdysone insect promoter No et al, Proc. Natl. Acad. Sci. USA,
• inducible promoters which may be useful in this context are those which are regulated by a specific physiological state, e.g., temperature, acute phase, a particular differentiation state of the cell, or in replicating cells only.
• the promoter is the CAG promoter. In some embodiments, the promoter is the SV40 promoter. In some embodiments, the promoter is the CMV promoter. In some embodiments, the promoter is a constitutive promoter. In some embodiments, the promoter is not a tissue or cell specific promoter. In some embodiments, the promoter is a tissue or cell specific promoter. In some embodiments, the promoter is not an inducible promoter.
• the native promoter for the Merlin product will be used.
• the native promoter can be used when it is desired that expression of Merlin should mimic the native expression.
• the native promoter may be used when expression of the transgene must be regulated temporally or developmentally, or in a tissue-specific manner, or in response to specific transcriptional stimuli.
• other native expression control elements such as enhancer elements, polyadenylation sites or Kozak consensus sequences may be included in the promoter sequence in order to more closely mimic the native expression.
• the transgene includes a gene operably linked to a tissue- specific promoter.
• the promoter is a neuron or neuronal tissue specific promoter. Examples of such promoters, include, but are not limited to, a neuron-specific enolase (NSE) promoter (Andersen et al., Cell. Mol. Neurobiok, 13:503-15 (1993)), a neurofilament light- chain gene (Piccioli et al., Proc. Natl. Acad Sci.
• NSE neuron-specific enolase
• microglia specific such as F4/80 (Rosario, A. M., Cruz, P. E., Ceballos-Diaz, C., Strickland, M. R., Siemienski, Z., Pardo, M., et al. (2016). Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol. Ther. Methods Clin. Dev. 3, 16026. doi: 10.1038/mtm.2016.26), or CD68 (Rosario, A. M., Cruz, P. E., Ceballos-Diaz, C., Strickland, M.
• GAG phosphate-activated glutaminase promoter
• GABAergic neuron specific such as glutamic acid decarboxylase promoter (GAD)( Rasmussen, M., Kong, L., Zhang, G. R., Liu, M., Wang, X., Szabo, G., et al. (2007).
• helper virus-free HSV-1 vectors containing the phosphate-activated glutaminase, vesicular glutamate transporter- 1, or glutamic acid decarboxylase promoter Brain Res. 1144, 19-32. doi: 10.1016/j. brainres.2007.01.125, among others.
• Other promoters can also be used, such as, but not limited to where expression in skeletal muscle is desired, a promoter active in muscle should be used.
• tissue specific promoters include, promoters that are tissue-specific are known for liver (albumin, Miyatake et al., J. Virol., 71:5124-32 (1997); hepatitis B virus core promoter, Sandig et al., Gene Ther., 3:1002-9 (1996); alpha-fetoprotein (AFP), Arbuthnot et al., Hum.
• transgene product The combination of the transgene product, the promoter/enhancer regulatory sequences, and 5' and 3' AAV ITRs can collectively be referred to as a “minigene” for ease of reference herein.
• the capsid used is taken from AAV9.
• the AAV9 capsid comprises a group of viral proteins (VP1, VP2, VP3, etc.) having the amino acid sequence of: amino acid residues 1 to 736 of SEQ ID NO: 3; amino acid residues 138 to 736 of SEQ ID NO: 3; or amino acid residues 203 to 736 of SEQ ID NO: 3.
• the AAV9 capsid comprises a group of viral proteins (VP1, VP2, VP3, etc.) having the amino acid sequence of amino acid residues 1 to 736 of SEQ ID NO: 3.
• the AAV9 capsid comprises a group of viral proteins (VP1, VP2, VP3, etc.) having the amino acid sequence of amino acid residues 138 to 736 of SEQ ID NO: 3. In some embodiments, the AAV9 capsid comprises a group of viral proteins (VP1, VP2, VP3, etc.) having the amino acid sequence of amino acid residues 203 to 736 of SEQ ID NO: 3.
• the AAV9 capsid comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to amino acid residues 1 to 736 of SEQ ID NO: 3; amino acid residues 138 to 736 of SEQ ID NO: 3; or amino acids 203 to 736 of SEQ ID NO: 3. In some embodiments, the AAV9 capsid comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to amino acid residues 1 to 736 of SEQ ID NO: 3.
• the AAV9 capsid comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to amino acid residues 138 to 736 of SEQ ID NO: 3. In some embodiments, the AAV9 capsid comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to amino acid residues 203 to 736 of SEQ ID NO: 3.
• the recombinant AAV genome encodes for the Merlin protein.
• the Merlin is isoform 1.
• the Merlin isoform 2.
• the Merlin protein encoded by the transgene comprises a sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical or homologous to a sequence of SEQ ID NO: 1 (isoform 1). In some embodiments, the Merlin protein encoded by the transgene comprises a sequence of SEQ ID NO: 1. In some embodiments, the recombinant AAV genome encodes for one or more active fragments of the Merlin protein.
• the one or more active fragments include, but not limited to, residues 1-359 of SEQ ID NO: 1, residues 1- 313 of SEQ ID NO: 1, residues 1-219 of SEQ ID NO: 1, residues 1-73 of SEQ ID NO: 1, residues 312-595 of SEQ ID NO: 1, residues 479-595 of SEQ ID NO: 1, residues 503-595 of SEQ ID NO: 1, or any combination thereof.
• the one or more active fragments include, but not limited to, residues 1-359 of SEQ ID NO: 1.
• the one or more active fragments include, but not limited to, residues 1-313 of SEQ ID NO: 1.
• the one or more active fragments include, but not limited to, residues 1-219 of SEQ ID NO: 1. In some embodiments, the one or more active fragments include, but not limited to, residues 1-73 of SEQ ID NO: 1. In some embodiments, the one or more active fragments include, but not limited to, residues 312-595 of SEQ ID NO: 1. In some embodiments, the one or more active fragments include, but not limited to, residues 479-595 of SEQ ID NO: 1. In some embodiments, the one or more active fragments include, but not limited to, residues 503-595 of SEQ ID NO: 1.
• the active fragments in some embodiments, can comprises a sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical or homologous to such fragments.
• the transgene comprises a nucleic acid molecule encoding a protein comprising a sequence of SEQ ID NO: 1, or an active fragment thereof.
• the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 2, or a sequence encoding the active fragments thereof.
• the nucleic acid molecule comprises a nucleic acid sequence that is least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2, or to the sequence encoding the active fragments thereof.
• variants of polypeptides or nucleic acid molecules described herein which include polypeptides or nucleic acid molecules having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with the amino acid sequences or nucleic acid molecules provided for herein or of the wild-type sequences.
• variants of Merlin include polypeptides having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity or sequence homology with the amino acid sequence of SEQ ID NO: 1, or an active fragment thereof.
• variants of nucleic acid molecules encoding Merlin include nucleic acid molecules having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with the SEQ ID NO: 2, or encoding an active fragment thereof are provided.
• the Merlin protein encoded by the transgene comprises a sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical or homologous to a sequence of SEQ ID NO: 8 (isoform 2).
• the Merlin protein encoded by the transgene comprises a sequence of SEQ ID NO: 8.
• the recombinant AAV genome encodes for one or more active fragments of the Merlin protein.
• the active fragments in some embodiments, can comprises a sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical or homologous to such fragments.
• the transgene comprises a nucleic acid molecule encoding a protein comprising a sequence of SEQ ID NO: 8, or an active fragment thereof.
• the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 9, or a sequence encoding the active fragments thereof.
• the nucleic acid molecule comprises a nucleic acid sequence that is least 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 9, or to the sequence encoding the active fragments thereof.
• variants of polypeptides or nucleic acid molecules described herein which include polypeptides or nucleic acid molecules having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with the amino acid sequences or nucleic acid molecules provided for herein or of the wild-type sequences.
• variants of Merlin include polypeptides having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity or sequence homology with the amino acid sequence of SEQ ID NO: 8, or an active fragment thereof.
• variants of nucleic acid molecules encoding Merlin include nucleic acid molecules having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with the SEQ ID NO: 9, or encoding an active fragment thereof are provided.
• sequence homology between two sequences (the terms are used interchangeably herein) are performed as follows.
• the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
• the optimal alignment is determined as the best score using the GAP program in the GCG software package with a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
• the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
• amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”.
• the percent identity between the two sequences is a function of the number of identical positions shared by the sequences.
• Variants of polypeptides described herein can be those having amino acid modifications (e.g., deletions, additions or substitutions, such as conservative substitutions) from the wild-type amino acid sequence of the polypeptide, or any active fragment thereof as described above.
• a variant of Merlin can differ by at least 1, 2, 3, 4, 5 but not more than 50, 40, 30, 20, 15 or 10 amino acids from Merlin (SEQ ID NO: 1 or SEQ ID NO: 8).
• the sequence may also have conservative amino acid substitutions.
• a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
• amino acids with basic side chains e.g., lysine, arginine, histidine
• acidic side chains e.g., aspartic acid, glutamic acid
• uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine
• nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
• beta-branched side chains e.g., threonine, valine, isoleucine
• aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine
• isolated protein or nucleic acid molecule refers to a purified protein or a nucleic acid molecule that is removed from at least 90% of at least one component of a natural sample from which the isolated protein or nucleic acid molecule can be obtained. Proteins can be “of at least” a certain degree of purity if the species or population of species of interest is at least 5, 10, 25, 50, 75, 80, 90, 92, 95, 98, or 99% pure on a weight-weight basis.
• the recombinant AAV can comprise AAV inverted terminal repeats (ITR).
• ITR AAV inverted terminal repeats
• the inverted terminal repeats used are the AAV-2 inverted terminal repeats. ITRs from other AAV serotypes may also be used and this is merely a nonlimiting example.
• AAV being the vehicle for delivering Merlin protein (e.g. by delivering DNA encoding for the Merlin protein)
• other vehicles can be used, such as adenovirus, retroviruses, lentiviruses, and the like. Therefore, in some embodiments, a recombinant virus for gene delivery is provided that encodes for Merlin protein, or an active fragment thereof, and expresses Merlin, or an active protein fragment thereof, in the infected cell.
• the AAV can also be pseudotyped with other viral structural or capsid proteins (non-AAV) to help specify the cell type that is infected by the AAV. Therefore, in some embodiments, the AAV is a pseudotyped AAV.
• compositions comprising the AAV or virus encoding for Merlin, or an active fragment thereof, are also provided.
• the composition comprises a recombinant virus encoding for Merlin, or an active fragment thereof, and a physiologically compatible carrier.
• the composition is a pharmaceutical composition and comprises a pharmaceutically acceptable carrier.
• pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the recombinant virus and not significantly deleterious to the recipient thereof.
• the composition or pharmaceutical composition comprises an effective amount of the virus. This can also be referred to as a therapeutically effective amount.
• a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result.
• a therapeutically effective amount of the composition may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the therapeutic to elicit a desired response in the individual.
• a therapeutically effective amount is also one in which any toxic or detrimental effects as a result of the composition are outweighed by therapeutically beneficial effects.
• compositions can comprise pharmaceutically acceptable vehicles, carrier, or excipients.
• pharmaceutically acceptable carriers vehicles useful in this disclosure are conventional. Remington’s Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, Pa., 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of one or more therapeutic compositions, and additional pharmaceutical agents.
• parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
• injectable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
• solid compositions for example, powder, pill, tablet, or capsule forms
• conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate.
• compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
• non-toxic auxiliary substances such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
• compositions may include one or more of the following: DMSO, sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer’s solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
• DMSO sterile diluents
• fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents
• antibacterial agents such
• nucleic acid molecules comprising a sequence that is at least 90%, 95%, 96%, 97%, 98%, or 99% identical of SEQ ID NO: 2.
• the nucleic acid molecule is an isolated nucleic acid molecule.
• the nucleic acid molecule comprises a sequence of SEQ ID NO: 2.
• SEQ ID NO: 2 can be used to distinguish between endogenous mRNA encoding for Merlin protein and the mRNA that is produced from the AAV encoding for the Merlin protein.
• SEQ ID NO: 2 is a non-limiting example of a sequence that is distinct from the native mRNA and another sequence that can be distinguished from the native sequence can be used.
• the method comprises contacting a sample with a probe that is specific to the AAV encoding mRNA and does not bind with the native mRNA and detecting the AAV mRNA when the probe binds to interacts with the AAV encoding mRNA.
• the method comprises performing RT-PCR on a sample with primers that are specific to the AAV encoding mRNA to detect the AAV encoded mRNA.
• the primers are specific to the AAV encoded mRNA and do not bind or interact with a native mRNA.
• the term “native mRNA” refers to a RNA that encoded by the cell’s or organisms original DNA that has not been modified, i.e. wild-type that has not been genetically manipulated. This type of assay, can be used, for example, in a subject that has been treated with the AAV compositions provided for herein to determine expression of the AAV encoding merlin protein, which is distinct from the native protein.
• the nucleic acid molecule comprises AAV inverted terminal repeats.
• the sequence of SEQ ID NO: 2 is bound within the AAV inverted terminal repeats.
• the AAV inverted terminal repeats are the AAV2 inverted terminal repeats.
• the nucleic acid comprising SEQ ID NO: 2 is operably linked to regulatory sequences which direct expression of the protein encoded by SEQ ID NO: 2.
• the regulatory sequences comprise a promoter.
• the promoter is as described herein.
• the promoter is a constitutive promoter or a tissue specific promoter.
• the promoter is a CAG promoter, a CMV promoter, or an SV40 promoter. In some embodiments, the promoter is a CAG promoter. In some embodiments, the promoter is a CMV promoter. In some embodiments, the promoter is an SV40 promoter. In some embodiments, the nucleic acid molecule is a plasmid.
• non-viral vectors are used.
• the compositions are provided that comprise the nucleic acid molecules described herein.
• the compositions comprise a carrier.
• the carrier is a transfection reagent or a reagent to facilitate the delivery of the nucleic acid molecule to a cell.
• the transfection reagent is a lipid based transfection reagent.
• the carrier is an electroporation agent.
• the nucleic acid molecules provided for herein can be used to produce an AAV that encodes for the Merlin protein.
• Methods of producing AAV are known to one of skill in the art and any method can be used.
• a non-limiting example is provided in U.S. Patent No. 7,906, 111, which is hereby incorporated by reference.
• the minigene can be carried on any suitable vector, e.g., a plasmid, which is delivered to a host cell.
• the plasmids may be engineered such that they are suitable for replication and, optionally, integration in prokaryotic cells, mammalian cells, or both.
• these plasmids (or other vectors carrying the 5' AAV ITR-heterologous molecule-3' AAV ITR) contain sequences permitting replication of the minigene in eukaryotes and/or prokaryotes and selection markers for these systems.
• Selectable markers or reporter genes may include sequences encoding geneticin, hygromicin or purimycin resistance, among others.
• the plasmids may also contain certain selectable reporters or marker genes that can be used to signal the presence of the vector in bacterial cells, such as ampicillin resistance.
• Other components of the plasmid may include an origin of replication and an amplicon, such as the amplicon system employing the Epstein Barr virus nuclear antigen.
• the molecule carrying the minigene is transfected into the cell, where it may exist transiently.
• the minigene (carrying the 5' AAV ITR-heterologous molecule-3' ITR) may be stably integrated into the genome of the host cell, either chromosomally or as an episome.
• the minigene may be present in multiple copies, optionally in head-to-head, head-to-tail, or tail-to-tail concatamers. Suitable transfection techniques are known and may readily be utilized to deliver the minigene to the host cell.
• the AAV comprises a nucleic acid molecule stuffer sequence upstream of the transgene and downstream of the 5’ (left) AAV ITR.
• the stuffer sequence comprises a sequence of SEQ ID NO: 6.
• the AAV comprises a nucleotide intron sequence that is downstream of the transgene and upstream of the right (3’) AAV (e.g., AAV2) ITR.
• the intron sequence is a HPRE sequence, such as those described herein.
• the HPRE sequence comprises a sequence of SEQ ID NO: 5.
• the vector when delivering the vector comprising the minigene by transfection, is delivered in an amount from about 5 pg to about 100 pg DNA, about 10 pg to about 50 pg DNA to about 1X10 4 cells to about 1X10 13 cells, or about 1X10 5 cells.
• the relative amounts of vector DNA to host cells may be adjusted, taking into consideration such factors as the selected vector, the delivery method and the host cells selected.
• the host cell itself for producing the AAV may be selected from any biological organism, including prokaryotic (e.g., bacterial) cells, and eukaryotic cells, including, insect cells, yeast cells and mammalian cells.
• the host cells are selected from among any mammalian species, including, without limitation, cells such as A549, WEH1, 3T3, 10T1/2, BHK, MDCK, COS 1, COS 7, BSC 1, BSC 40, BMT 10, VERO.
• W138, HeLa, 293 cells which express functional adenoviral El), Saos-2, C2C12, L cells, HT1080, HepG2 and primary fibroblast, hepatocyte and myoblast cells derived from mammals including human, monkey, mouse, rat, rabbit, and hamster.
• the requirements for the cell used is that it not carry any adenovirus gene other than El, E2a and/or E4 ORF6, which is done to avoid homologous recombination of a contaminating virus during the production of AAV; and it is capable of infection or transfection of DNA and expression of the transfected DNA.
• the host cell is stably transfected with the capsid protein, such as AAV9 capsid. It can also have the rep protein being produced from the same cell. Alternatively, these proteins can be encoded for on separate plasmids that encode for the viral proteins and are transfected into the cell at the same time or sequentially into the host cell to produce the AAV encoding for Merlin.
• the host cell that could be used is a host cell stably transformed with the sequences encoding rep and cap, and which is transfected with the adenovirus El, E2a, and E40RF6 DNA and a construct carrying the minigene as described above.
• Stable rep and/or cap expressing cell lines such as B-50 (International Patent Application Publication No. WO 99/15685), or those described in U.S. Pat No. 5,658,785, may also be similarly employed.
• Another example of a host cell is one that contains the minimum adenoviral DNA which is sufficient to express E4 ORF6.
• Yet other cell lines can be constructed using the AAV9 cap sequences provided for herein.
• the preparation of a host cell involves techniques such as assembly of selected DNA sequences. This assembly may be accomplished utilizing conventional techniques. Such techniques include cDNA and genomic cloning, which are well known and are described in Sambrook et ah, cited above, use of overlapping oligonucleotide sequences of the adenovirus and AAV genomes, combined with polymerase chain reaction, synthetic methods, and any other suitable methods which provide the desired nucleotide sequence.
• Introduction of the molecules (as plasmids or viruses) into the host cell may also be accomplished using techniques known to the skilled artisan and as discussed throughout the specification.
• standard transfection techniques are used, e.g., CaPCri transfection, lipid based transfection, or electroporation, and/or infection by hybrid adenovirus/ AAV vectors into cell lines such as the human embryonic kidney cell line HEK 293 (a human kidney cell line containing functional adenovirus El gene which provides trans-acting El proteins).
• the AAV9 capsid protein can also be used to pseudotype other viruses encoding for Merlin. Thus, they could be used in other rAAV and non-rAAV vector systems. Such vectors systems may include, e.g., lentiviruses, retroviruses, poxviruses, vaccinia viruses, and adenoviral system, among others.
• methods of producing an AAV as provided for herein are provided.
• the method comprises contacting a cell with a nucleic acid molecule as provided herein or a composition of the same to produce the AAV.
• the cell is an AAV packaging cell line.
• the AAV packaging cell line is an AAV9 packaging cell line, such as those described herein or in U.S. Patent No. 7,906,111, which is hereby incorporated by reference in its entirety.
• a cultured host cell comprises a recombinant nucleic acid molecule encoding an AAV capsid protein and a recombinant nucleic acid molecule encoding Merlin protein.
• the capsid protein is the AAV9 capsid protein or variants thereof as described herein.
• methods of delivering a Merlin protein to a cell are provided.
• the methods comprise contacting the cell with an AAV or virus encoding for Merlin, such as those described herein.
• the methods comprise non-viral delivery methods, such as needle injection, ballistic DNA injection, sono-poration, photo-poration, magneto-fection, hydro-poration, or electro-poration, transfection, and any combination thereof.
• the non-viral methods comprise a liposome or a polymer carrier, and a combination thereof, for delivery of the genetic material encoding Merlin protein.
• methods of treating a subject with NF2, or other merlin deficiency comprising administering to the subject with NF2, or other merlin deficiency, a virus or an AAV encoding for Merlin, such as those provided herein.
• the method of administration can be any suitable method, such as those described herein.
• the administration is intrathecal, intravenous, intrapleural, or intratumoral.
• methods of inhibiting the growth of a schwannoma, a meningioma, mesothelioma, or an ependymoma in a subject are provided.
• the method comprises administering to the subject virus or an AAV encoding for Merlin, such as those provided herein.
• the method of administration can be any suitable method, such as those described herein.
• the administration is intrathecal, intraci sternal intravenous, intrapleural, or intratumoral.
• NF2 deficiency refers to a condition or disorder in a subject that is caused by a mutated or inactivated Merlin protein. This can also be referred to as a “Merlin deficiency.” These conditions can be the various types of tumors or disorders provided herein. In some embodiments, the disorder is as provided herein.
• the disorder is cataracts, retinal detachment, damage to the nerves of the eye, papilledema (optic disc edema), ocular migraine (retinal migraine), retinitis pigmentosa (RP) (retinal degeneration), combined hamartoma of the retina and RPE, retinal microaneurysms, epiretinal membrane conjunctivitis, physiopedia (severe dry eyes), nystagmus-oscillopsia (ocular flutter/cross), diplopia (double vision), or gaze-evoked tinnitus (GET).
• cataracts cataracts, retinal detachment, damage to the nerves of the eye
• papilledema optical disc edema
• ocular migraine retina migraine
• RP retinitis pigmentosa
• GET gaze-evoked tinnitus
• a method of treating a subject with a disorder, or at risk of a disorder, associated with merlin deficiency is provided, and the method comprises administering to the subject an AAV, such as those provided herein.
• AAV neurofibromatosis type 2, schwannomatosis, or a cancer
• methods of preventing the growth or formation of a spinal schwannomas or a meningioma in a subject are provided.
• the method comprises administering to the subject virus or an AAV encoding for Merlin, such as those provided herein.
• the method of administration can be any suitable method, such as those described herein.
• the administration is intrathecal, intravenous, or intratumoral.
• the subject is a subject with NF2.
• methods of treating a subject with a disorder, or at risk of a disorder, associated with merlin are provided.
• the method comprises administering to the subject virus or an AAV encoding for Merlin, such as those provided herein.
• the method of administration can be any suitable method, such as those described herein.
• the administration is intrathecal, intravenous, intrapleural, or intratumoral.
• the subject is a subject with NF2.
• the disorder is neurofibromatosis type 2, schwannomatosis, schwannomas (e.g., vestibular schwannomas); a cancer (e.g., a hematological cancer (e.g., juvenile myelomonocytic leukemia), a leukemia (e.g., adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia, adult acute myeloid leukemia, childhood acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, or hairy cell leukemia); a lymphoma (e.g., AIDS-related lymphoma, cutaneous T-cell lymphoma, adult hodgkin lymphoma, childhood hodgkin lymphoma, adult non-hodgkin lymphoma, childhood non- hodgkin lymphoma, primary central nervous system lymphom, sezary syndrome, cutaneous T-cell lymphoma,
• the disorder is cataracts, retinal detachment, damage to the nerves of the eye, papilledema (optic disc edema), ocular migraine (retinal migraine), retinitis pigmentosa (RP) (retinal degeneration), combined hamartoma of the retina and RPE, retinal microaneurysms, epiretinal membrane conjunctivitis, physiopedia (severe dry eyes), nystagmus-oscillopsia (ocular flutter/cross), diplopia (double vision), or gaze-evoked tinnitus (GET).
• cataracts cataracts, retinal detachment, damage to the nerves of the eye
• papilledema optical disc edema
• ocular migraine retina migraine
• RP retinitis pigmentosa
• GET gaze-evoked tinnitus
• compositions, and methods are described in terms of “comprising” various components or steps (interpreted as meaning “including, but not limited to”), the compositions, methods, and devices can also “consist essentially of’ or “consist of’ the various components and steps, and such terminology should be interpreted as defining essentially closed-member groups.
• the terms “co-administration” or the like are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.
• the term “subject” or “patient” as used herein includes, but is not limited to, humans and non-human vertebrates such as wild, domestic, and farm animals.
• the subject or patient described herein is an animal.
• the subject or patient is a mammal.
• the subject is a human.
• the subject or patient is a non-human animal.
• the subject or patient is a non-human mammal.
• the subject or patient is a domesticated animal, such as a dog, cat, cow, pig, horse, sheep, or goat.
• the subject or patient is a companion animal such as a dog or cat.
• the subject or patient is a livestock animal such as a cow, pig, horse, sheep, or goat.
• the subject or patient is a zoo animal.
• the subject or patient is a research animal such as a rodent, dog, or non-human primate.
• the subject or patient is a nonhuman transgenic animal such as a transgenic mouse or transgenic pig.
• treat refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to inhibit, prevent or slow down (lessen) an undesired physiological condition, disorder or disease, or to improve, inhibit, or otherwise obtain beneficial or desired clinical results.
• beneficial or desired clinical results include, but are not limited to, improvement or alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease; and prevention of disorder or disease manifestation.
• Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment.
• Encoding refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA or viral RNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom.
• a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system.
• Both the coding strand the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.
• endogenous refers to any material from or produced inside an organism, cell, tissue or system.
• exogenous refers to any material introduced from or produced outside an organism, cell, tissue or system.
• expression is defined as the transcription and/or translation of a particular nucleotide sequence driven by its promoter.
• “Expression vector” refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed.
• An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system.
• Expression vectors include all those known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes) and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno- associated viruses) that incorporate the recombinant polynucleotide.
• the expression vector is the alphaviruses as described herein.
• Preventing refers to inhibiting the full development of a disease. “Treating” refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop. “Ameliorating” refers to the reduction in the number or severity of signs or symptoms of a disease. Formulations and Routes for Administration to Patients
• compositions expression constructs, viruses, expression vectors, fused proteins, transfected or transduced cells, in a form appropriate for the intended application.
• this will entail preparing compositions that are essentially free of pyrogens, except for the viruses or plasmids provided for herein, as well as other impurities that could be harmful to humans or animals.
• the recombinant nucleic acids, virus products or pharmaceutical compositions thereof may be delivered, for example at doses of about 1-5 million particles per dose.
• Vials or other containers may be provided containing the product, for example, a volume per vial of about 0.25 ml to about 10 ml, for example, about 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 ml, for example, about 2 ml.
• compositions that do not produce a significant adverse, allergic, or other untoward reactions when administered to an animal or a human.
• a pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is known. Except insofar as any conventional media or agent is incompatible with the vectors or cells, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
• solutions can be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
• the formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like.
• the solution may be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
• aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
• sterile aqueous media can be employed.
• one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, “Remington’s Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations may meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologies standards.
• compositions may be formulated for aerosolized delivery to a subject.
• the compositions described may be formulated in aqueous solutions such as water or in physiologically compatible buffers such as Hanks’s solution, Ringer’s solution, or physiological saline buffer.
• the solution may contain one or more formulatory agents such as suspending, stabilizing or dispersing agents.
• Delivery systems of the disclosure that deliver the polynucleotides of the disclosure to a desired cell of a subject are not limited to the viruses of the disclosure.
• the delivery vector comprises a virus as provided for herein. These can be used in methods of treating disorders or conditions, such as those described herein.
• the therapeutic is administered at least every 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 2 years, three years, four years, five years, six years or more.
• the therapeutic is administered intravenously, intradermally, subcutaneously, intrathecally, which includes which includes intraventricularly, intracisternally, or injections into lumbar locations, intra-ci sterna magnally, intrapleurally, intravitreally, subretinally, intramuscularly, systemically, or locally, such as intratumoral injection.
• kits can be provided.
• any of the recombinant nucleic acids, or, viruses can be provided frozen or refrigerated and packaged as a kit, alone or along with separate containers of any of the other agents from the pre-conditioning or post-conditioning steps, and optional instructions for use.
• kits may comprise ampoules, disposable syringes, capsules, vials, tubes, or the like.
• the kit may comprise a single dose container or multiple dose containers comprising the topical formulation of embodiments herein.
• each dose container may contain one or more unit doses.
• the kit comprises a pre-filled syringe containing a pharmaceutical composition.
• the kit may include an applicator.
• the kits include all components needed for the stages of conditioning/treatment.
• the cellular compositions may have preservatives or be preservative-free (for example, in a single-use container).
• the recombinant nucleic acids, virus products may be prepared and frozen or refrigerated at a desired stage, suitable for shipping to a hospital or treatment center.
• AAV9 CAPSID (SEQ ID NO: 3)
• Example 1 AAV Design Encoding for Merlin Isoform 1. An AAV plasmid to produce an AAV vector encoding for Merlin Isoform 1 was designed. The transgene was subcloned into pAV-ACG (Vigene Biosciences) at the Kpnl and Xhol sites. The entire AAV genome (excluding the ITRs) was sequence confirmed.
• Isoform 1 of Merlin Isoform 2 of Merlin could also be used in its place.
• Example 2 Vector can express Merlin protein
• An AAV9 vector was used to transduce HEK293 cells, the vector can be based off a plasmid s shown in FIG. 1 or FIG. 2.
• the AAV9 vector comprised a transgene encoding for Merlin protein.
• the cells were analyzed for expression of Merlin protein and was detected. These results are illustrated in FIG. 3, which shows a Western Blot detecting the expression of the protein.
• Example 3. Viral Delivery of Merlin to treat NF2.
• AAV adeno-associated virus
• CNS central nervous system
• the AAV is administered by intrathecal injection, but could also be administered by multiple intertumoral injections, intraventricularly, or intravenously.
• the expression of Merlin in the CNS halts tumor progression and/or leads to tumor regression.
• the AAV comprises the AAV capsid, and the NF2 transgene operatively connected to a constitutive promoter.
• the AAV is based on AAV-DJ (Grimm D, et al.
• NF2 transgene is a human sequence-optimized neurofibromatosis 2 (NF2) gene, which can also be referred to as “h-soNF2.”
• NF2 human sequence-optimized neurofibromatosis 2
• the isoform of NF2 being used will be the longest (595 amino acids), but other isoforms, or active fragments thereof, could be used in its place.
• Example 4 Expression of NF2 reduces spinal schwannomas in NF2 transgenic mice and meningioma xenografts in nude (SCID) mice.
• the AAV of Example 1 is delivered intrathecally to adult transgenic NF2 mice with spinal schwannomas or nude mice with meningioma xenografts. The mice are monitored, and then upon sacrifice tumor cells and normal Schwann and arachnoid cells are harvested. The presence of full length human merlin is confirmed via western blot. Volumetric measurements of tumors are made and the tumor burden is found to be reduced.
• Example 5 AAV-NF2 is functional in cell culture models of neurofibromatosis type 2. Initially the AAV of Example 1, is used to deliver the merlin gene to cells and the gene is functional and produces the merlin protein. Human merlin production from the AAV-delivered transgene is assessed by western blot method using human merlin-specific antibodies.
• the cell line can be, for example, a RT4 Rat Schwannoma Cell line. Colony formation assays are performed as well and the AAV-NF2 is found to reduce colony formation in a soft agar assay.
• pAV-CAG-Merlin-V2 was generated by modifying sequences elements in the original Merlin construct (pAV-CAG-Merlin) as shown in FIG. 1 and FIG. 2. The cloning strategy is based on the nucleotide position in the original Merlin Construct.
• pAV-CAG-Merlin-V2 is an recombinant adeno-associated virus (AAV) DNA plasmid with 6892 base pair (bp) in size (FIG.
• AAV adeno-associated virus
• ITR is modified to include a stuffer sequence, which can be used to confer optimal AAV packaging efficiency.
• a HPRE sequence is inserted downstream of sequences encoding the Merlin protein in order to facilitate transgene expression.
• the vector was modified to include a Kanamycin resistance gene for ease of manufacture of the DNA product used in recombinant AAV production.
• the expression cassette is comprised of a CAG promoter coupled to sequence encoding a codon optimized Merlin protein followed by a post-transcriptional regulatory element of hepatitis B virus (HPRE) and then a transcription termination SV40 Polyadenylation (SV40- polyA) sequence.
• HPRE element is a cis-acting sequence that facilitates the cytoplasmic localization of intronless transcripts and contributes to higher gene expression.
• a 400 bp stuffer sequence derived from the intron 1 region of the Hypoxanthine Phospho-ribosyl-transferase 1 (HPRTl) gene is inserted downstream of the left
• Kanamycin resistance gene is included in the plasmid backbone as a selection marker.
• the Left-ITR can comprise:
• a vector was created that removes any artificial tags, such as a histidine tag or
• Transgenes carried by a gene therapy vector are mostly devoid of intron sequences. Intronless transcripts can be less stable and prone to accumulation inside the nucleus.
• Posttranscriptional regulatory elements (PREs) of Hepatitis B virus (HPRE) can increase accumulation of the cytoplasmic mRNA of an intronless gene by promoting mRNA exportation from the nucleus to the cytoplasm, enhancing 3' end processing and stability. Therefore, a HPRE element is added to the recombinant Merlin transcript to improve transgene mRNA stability and transgene expression.
• the HPRE fragment is synthesized and inserted between Xhol site (2906) and EcoRV site (3000).
• the Posttranscriptional regulatory elements (PREs) of Hepatitis B virus (HPRE) can be as follows:
• a stuff er sequence is introduced at the 5’ end of the construct in front of the CAG promoter.
• the optimal packaging size of an AAV vector is 4.1-4.9 kb (Grieger et al. 2005).
• the packaging size of the original Merlin construct was just 3.5 kb.
• a 400 bp stuffer sequence derived from the intron 1 region of the HPRT1 gene is inserted downstream of the left ITR sequence and upstream of the CAG promoter sequence. With this sequence addition, the AAV is increased to facilitate efficient packaging into the AAV capsid.
• a HPRT1 intron 1 sequence is used as a stuffer sequence, but other stuffer sequences can be used:
• the stuffer sequence can be as follows:
• FIG. 4 shows immunohistochemistry images of biodistribution of eGFP in the cerebellum of in cynomolgus macaques dosed with AAV9-CAG-eGFP by ICM administration.
• These data use surrogate biomarker biodistribution demonstrate that AAV9 vectors provided by the ICM route of administration can express a protein in proper tissues and perhaps provide evidence that AAV9 vectors expressing the merlin protein can restore normal merlin function.
• the eGFP expression was used as a surrogate marker for Merlin expression since the animal expresses native Merlin protein, which was not distinguishable from the merlin expressed from the AAV9 vector.
• Example 8 In NF2 Knockout Mice Administered with AAV9-CAG-Merlin v2 There was a Reduction in Density of Schwann Cells vs Mice Treated with AAV9-CAG-GFP.
• Postn-Cre;Nf2 flox/flox mice were injected into the cisternal magna (ICM) with 5 ⁇ L or 10 pL of test article (AAV9-CAG-Merlin or AAV9-CAG-Merlin-v2) or a negative control vector (AAV9-CAG-GFP).
• Group la 4 x 1 month old pups injected with AAV9-CAG-GFP (low dose control, 5.6 E12 vg/kg)
• Group lb 4 x 1 month old pups injected with AAV9-CAG-GFP (high dose control, 4E13 vg/kg)
• Group 2a 10 x 1 month old pups injected with AAV9-CAG-Merlin vl (low dose, 5.6 E12 vg/kg)
• Group 2b 10 X 1 month old pups injected with AAV9-CAG-Merlin v2 (high dose 7 El 3 vg/kg)
• Group 3 5 x 1 month old pups injected with AAV-GFP (low dose control, 5.6 E12 vg/kg) sacrificed at 4 weeks post injection to analyze tissue distribution.
• mice Post dosing mice were observed for 5 months (groups la, lb, 2a, 2b), or 4 weeks (group 3).
• Two Group lb mice (AAV9-CAG-GFP) were sacrificed after 22 days, and 50 days respectively due to excessive weight loss. Following the post dosing observation period, mice were sacrificed for further analysis.
• SC Schwann cell
• DRG Dorsal Root Ganglion
• Immunohistochemistry with GFP antibodies were used to analyze AAV-GFP expression and tissue distribution (Group 3) and persistence of AAV-GFP expression at 6 months (Group 2).
• Enhanced immunofluorescence analyses demonstrated the presence of eGFP expression in the cells surrounding axonal cells (Schwan cells) in a mouse administered with a low dose (group 3; 5.6 E12 vg/kg) of AAV9-CAG-GFP via ICM administration and was sacrificed 4 weeks later (FIG. 6).
• the nerve distal to the DRG also showed expression of eGFP in Schwann cells (FIG. 7).
• a section the full width of a DRG demonstrated distributed expression of eGFP across the full area of the DRG.
• CAG-Merlin-v2 the number of nuclei per square micron of tissue were counted in AAV9-CAG- Merlin and AAV9-CAG-Merlin-v2 treated animals and compared against mice dosed with the negative control of AAV9-CAG-eGFP.
• a statistically significant reduction in number of SC nuclei/pm 2 was observed in the high dose arm of AAV9-CAG-Merlin-v2 as compared to similar mice administered with an equivalent dose of AAV9-CAG-GFP.
• a small reduction (not statistically significant) in # SC nuclei/pm 2 was observed in the low dose arm of AAV9-CAG- Merlin v2 as compared with AAV9-CAG-GFP.
• SC 8 shows significant reduction in the density of Schwann cell (SC) nuclei (nuclei/pm 2 ) in cross-sections of DRG from 6 month old Postn- Cre;Nf2 flox/flox mice 5 months post AAV9-CAG-Merlin administration compared to AAV9-CAG- GFP injected controls.
• SC Schwann cell
• compositions and methods have been shown and described with reference to specific illustrative non-limiting embodiments, it should be understood that various changes in form and detail may be made without departing from the spirit and scope of the present disclosure. Therefore, all embodiments that come within the scope and spirit of the present disclosure, and equivalents thereto, are intended to be claimed.
• the claims, descriptions and diagrams of the compositions, methods, systems, and assays of the present disclosure should not be read as limited to the described order of elements unless stated to that effect.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Genetics & Genomics (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Zoology (AREA)
• General Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Biotechnology (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Medicinal Chemistry (AREA)
• Microbiology (AREA)
• Physics & Mathematics (AREA)
• Virology (AREA)
• Plant Pathology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Gastroenterology & Hepatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Oncology (AREA)
• Toxicology (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=84425523

Family Applications (1)

Country Status (5)

Cited By (3)

Families Citing this family (1)

Citations (5)

Family Cites Families (1)

• 2022
  • 2022-06-08 JP JP2023575918A patent/JP2024520815A/ja active Pending
  • 2022-06-08 EP EP22820962.3A patent/EP4352079A4/en not_active Withdrawn
  • 2022-06-08 WO PCT/US2022/032679 patent/WO2022261209A1/en not_active Ceased
  • 2022-06-08 US US17/835,566 patent/US20230056226A1/en not_active Abandoned
  • 2022-06-08 CN CN202280049047.XA patent/CN117813314A/zh active Pending

Patent Citations (5)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events